Bloomage Raises $85 Million for Aesthetic Products in China

Bloomage BioTechnology, a China maker of aesthetic drug products, announced an $85 million investment from GIC, Singapore's sovereign fund. Bloomage makes hyaluronic acid API and finished products. Earlier this year, the company set up a JV with Korea's Medytox to develop Medytox's botulinum toxin business in China. Bloomage said the GIC investment will help build its aesthetic medical business through organic growth and acquisitions. More details.... Stock Symbols: (HK: 963) (KS: 086900) Share this with colleagues: // //